查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1837443

口服疫苗市場（按疫苗類型、適應症、年齡層和分銷管道分類）—2025-2032 年全球預測

Oral Vaccine Market by Vaccine Type, Disease Indication, Age Group, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年口服疫苗市場規模將成長至 300.6 億美元，複合年成長率為 6.68%。

主要市場統計數據
基準年2024年 179.1億美元
預計2025年 190.9億美元
預測年份：2032年 300.6億美元
複合年成長率（%） 6.68%

全面介紹口服疫苗的創新、公共衛生相關性、科學進步以及全球策略和商業性影響

口服疫苗已成為預防醫學領域不斷發展的關鍵工具，在給藥、分發和患者接受度方面具有顯著優勢。過去十年，製劑科學、黏膜免疫學和給藥技術的進步匯聚在一起，重新激發了研發人員和公共衛生官員的興趣。這些創新旨在減少針頭疫苗接種的障礙，提高疫苗的耐熱性以減少低溫運輸黏膜免疫反應更有效地阻斷病原體傳播。

隨著相關人員重新評估免疫策略，口服疫苗提案不僅提供了便利，還可能提高供應鏈效率並降低管理成本。在臨床上，口服疫苗接種有助於開展針對缺乏訓練有素的醫護人員地區的大規模疫苗宣傳活動和項目，從而實現公平目標。同時，科學界正在不斷改進抗原呈現、佐劑選擇和載體設計，以提高包括兒童和老年人群在內的不同人群的免疫抗原性。

本導言旨在對口服疫苗開發和商業化的促進因素、障礙和策略考量進行細緻的探討。它強調了科學創新、監管趨勢和分銷模式之間的相互作用，這些因素共同決定了口服疫苗從有希望的候選疫苗轉變為全球免疫計劃常規組成部分的速度。本導言旨在提供一個平衡的基準，隨後的章節重點關注不斷變化的情況、貿易影響、細分動態、區域差異、企業策略以及對整個生態系統領導者的實用建議。

分析正在重新定義口服疫苗開發和交付範式的變革性科學、監管、分銷和患者主導的轉變

在技​​術突破、相關人員期望變化和法律規範不斷演變的推動下，疫苗領域正在經歷一場變革性的轉變。在科學層面，mRNA平台、載體設計和抗原穩定性的進步，使得以往難以實現的口服給藥方式成為可能。此外，製劑科學的改進也為這些進步提供了補充，這些改進可以保護不穩定分子免受胃腸道分解，並靶向誘導粘膜免疫。因此，研發重點日益集中在持續的黏膜免疫、節省劑量的策略和便捷的給藥方式。

同時，公共衛生重點正轉向建構具有韌性的免疫系統，以應對地方性和突發性威脅。這種對韌性的關注有利於簡化物流的方法，例如無針給藥和低溫運輸要求較低的製劑。監管機構正在不斷改進其指導方針，以適應新的給藥技術，並為銜接臨床試驗和真實世界證據生成創建更清晰的途徑。私營部門投資者和策略合作夥伴正在透過重新平衡其投資組合來應對，將早期口服候選藥物和擴充性的平台技術納入其中。

此外，終端用戶的期望和醫療保健服務模式正在重塑商業性模式。患者和看護者越來越重視便利性和微創性，這推動了口服疫苗在社區和門診的普及。數位醫療工具和遠端醫療也透過實現疫苗接種計畫、依從性追蹤和遠端監控，影響疫苗的配送。這些轉變共同創造了一個充滿活力的競爭環境，將科學可行性、監管清晰度、以患者為中心的設計和分銷創新有機結合，加速口服疫苗概念轉化為實踐。

評估 2025 年美國關稅如何重塑供應鏈策略、採購動態和製造在地化

美國2025年實施的關稅政策變化的累積效應，為疫苗開發商、製造商和採購實體帶來了新的考量。這些貿易措施雖然與更廣泛的產業戰略目標一致，但也影響到疫苗價值鏈中的多個環節，包括原料藥、輔料、專用包裝材料以及灌裝和表面處理工程所用設備的採購。因此，擁有全球分散式供應鏈的公司必須重新評估籌資策略和成本結構，以降低進口關稅上調和港口處理延誤帶來的風險。

從實際角度來看，這項政策轉變正在加速圍繞供應鏈在地化、雙重採購以及關鍵投入品策略性儲備的討論。製造商正在探索近岸外包選項，並擴大與國內合約研發和製造外包合作夥伴的關係，以緩解關稅相關的脆弱性。這些變化也影響供應商合約談判的動態，更重視價格透明度、運費最佳化和風險共用協議。採購團隊擴大模擬關稅對其營運的下游影響，包括前置作業時間和存貨周轉的變化，以保持臨床項目和疫苗宣傳活動的供應連續性。

對於官方採購商和貸款機構而言，關稅導致預算和採購時間表更加複雜，從而重新燃起人們對長期供應協議的興趣，並鼓勵在關稅優惠管轄區內進行製造業投資。重要的是，政策環境鼓勵跨部門合作，以平衡國家戰略目標與全球衛生需求，包括開展多邊對話，以確保關稅措施不會妨礙獲得救命疫苗。展望未來，疫苗產業正在透過一系列營運韌性措施、策略夥伴關係和有針對性的資本投資進行調整，旨在保持專案的連續性，同時應對不斷變化的貿易現實。

整合疫苗平台類型、目標疾病、人口需求和分銷管道的關鍵細分洞察，為開發和商業化選擇提供參考

了解市場需要從產品、臨床、人口統計和分銷等維度建立系統視角，每個維度都決定了開發重點和商業性方法。基於疫苗類型的市場分析考慮了結合疫苗、去活化疫苗、減毒疫苗、mRNA疫苗和次單位疫苗，並認知到每種平台都存在配方挑戰和適合口服的免疫學特性。這些差異會影響關於抗原穩定性、給藥方案以及保護性輔料和遞送載體選擇的決策。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 增加益生菌口服疫苗製劑的投資，以增強黏膜免疫
  • 監管部門的核准加速了新興市場低溫運輸口服疫苗的開發
  • 採用可食用植物口服疫苗，降低生產成本，提高病患遵從性
  • 奈米技術載體在口服疫苗平台中靶向遞送抗原的整合
  • 口服脊髓灰質炎疫苗根除宣傳活動在策略性國際夥伴關係和資金支持下擴展

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章口服疫苗市場（依疫苗類型）

  • 結合疫苗
  • 去活化疫苗
  • 減毒活疫苗
  • mRNA疫苗
  • 次單位疫苗

9. 口服疫苗市場（依疾病適應症）

  • 流感
  • 諾羅病毒
  • 脊髓灰質炎
  • 輪狀病毒

第 10 章口服疫苗市場（依年齡層）

  • 成人
  • 老年人
  • 孩子們

第 11 章口服疫苗市場（依通路）

  • 醫院和診所
  • 網路藥局
  • 藥局

第12章口服疫苗市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章口服疫苗市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 口服疫苗市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • AstraZeneca plc
    • Bharat Biotech International Limited
    • Emergent BioSolutions Inc.
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Moderna, Inc
    • PT Bio Farma（Persero）
    • Sanofi SA
    • Sinovac Biotech Ltd
    • Valneva SE
Product Code: MRR-035DA3C63714

The Oral Vaccine Market is projected to grow by USD 30.06 billion at a CAGR of 6.68% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 17.91 billion
Estimated Year [2025] USD 19.09 billion
Forecast Year [2032] USD 30.06 billion
CAGR (%) 6.68%

Comprehensive introduction framing oral vaccine innovation, public health relevance, scientific advancements, and strategic commercial implications worldwide

Oral vaccines are emerging as a pivotal modality in the evolving landscape of preventive medicine, offering distinct advantages across administration, distribution, and patient acceptance. Over the past decade, advances in formulation science, mucosal immunology, and delivery technologies have converged to renew interest from developers and public health authorities alike. These innovations seek to reduce barriers associated with needle-based vaccination, improve thermostability to ease cold chain burdens, and exploit mucosal immune responses to interrupt pathogen transmission more effectively.

As stakeholders reassess immunization strategies, the oral vaccine proposition extends beyond convenience to encompass supply chain efficiencies and potential cost reductions in administration. In clinical contexts, oral delivery can facilitate mass immunization campaigns and targeted programs where trained personnel are scarce, thereby supporting equity goals. Concurrently, the scientific community continues to refine antigen presentation, adjuvant selection, and vector design to enhance immunogenicity across demographic groups, including pediatric and geriatric populations.

This introduction sets the stage for a nuanced examination of the drivers, barriers, and strategic considerations shaping oral vaccine development and commercialization. It emphasizes the interplay between scientific innovation, regulatory pathways, and distribution models, which collectively determine the pace at which oral vaccines transition from promising candidates to routine components of global immunization programs. The aim is to provide a balanced baseline that informs subsequent sections focused on landscape shifts, trade implications, segmentation dynamics, regional variations, corporate strategies, and pragmatic recommendations for leaders across the ecosystem.

Analysis of the transformative scientific, regulatory, distributional, and patient-driven shifts redefining the oral vaccine development and delivery paradigm

The vaccine landscape is undergoing transformative shifts driven by technological breakthroughs, altered stakeholder expectations, and evolving regulatory frameworks. At the scientific level, progress in mRNA platforms, vector design, and antigen stabilization is enabling new approaches to oral delivery that were previously impractical. These advances are complemented by improvements in formulation science that protect labile molecules from gastrointestinal degradation and target mucosal immune induction. As a result, development priorities are increasingly centered on durable mucosal immunity, dose-sparing strategies, and simplified administration.

Concurrently, public health priorities have shifted toward resilient immunization systems that can respond to both endemic pathogens and emergent threats. This focus on resilience favors modalities that simplify logistics, such as needle-free administration and formulations with relaxed cold chain requirements. Regulatory agencies are evolving their guidance to accommodate novel delivery technologies, creating clearer pathways for bridging trials and real-world evidence generation. Private sector investors and strategic partners are responding by rebalancing portfolios to include early-stage oral candidates and platform technologies that promise scalability.

Moreover, end-user expectations and healthcare delivery models are reshaping commercial approaches. Patients and caregivers increasingly prioritize convenience and minimal invasiveness, which supports the adoption of oral vaccines in community and outpatient settings. Digital health tools and telemedicine are also influencing vaccine delivery by enabling scheduling, adherence tracking, and remote monitoring. Taken together, these shifts create a dynamic playing field where scientific feasibility, regulatory clarity, patient-centered design, and distribution innovation intersect to accelerate the translation of oral vaccine concepts into practice.

Evaluation of how United States tariff measures enacted in 2025 have reshaped supply chain strategies, procurement dynamics, and manufacturing localization considerations

The cumulative impact of tariff policy changes enacted in the United States in 2025 has introduced a new set of considerations for vaccine developers, manufacturers, and procurement entities. These trade measures, while aimed at broader industrial strategy objectives, affect multiple nodes of the vaccine value chain, including the sourcing of active pharmaceutical ingredients, excipients, specialized packaging materials, and equipment used in fill-and-finish operations. As a consequence, organizations with globally distributed supply chains must reassess sourcing strategies and cost structures to mitigate exposure to increased import duties and procedural delays at ports.

In practical terms, the policy shift has accelerated conversations around supply chain localization, dual sourcing, and strategic stockpiling of critical inputs. Manufacturers are investigating nearshoring options and expanding relationships with domestic contract development and manufacturing organizations to reduce tariff-related vulnerabilities. These changes also influence contract negotiation dynamics with suppliers, where greater emphasis is placed on price transparency, freight optimization, and shared risk agreements. Procurement teams are increasingly modeling the downstream operational implications of tariffs, such as altered lead times and inventory turnover, to preserve continuity of supply for clinical programs and immunization campaigns.

For public purchasers and financing institutions, tariffs introduce complexities in budgeting and procurement timelines, prompting renewed interest in long-term supply agreements and incentivized manufacturing investments within tariff-favored jurisdictions. Importantly, the policy environment has encouraged cross-sector collaboration to balance national strategic goals with global health imperatives, including multilateral dialogues to ensure that tariff measures do not impede access to life-saving vaccines. Looking ahead, the industry is adapting through a combination of operational resilience measures, strategic partnerships, and targeted capital investments aimed at maintaining programmatic continuity while aligning with evolving trade realities.

Key segmentation insights integrating vaccine platform types, disease targets, demographic needs, and distribution channels to inform development and commercialization choices

Understanding the market requires a structured view across product, clinical, demographic, and distribution dimensions, each of which shapes development priorities and commercial approaches. Based on Vaccine Type, market analyses consider Conjugate Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, mRNA Vaccines, and Subunit Vaccines, recognizing that each platform presents distinct formulation challenges and immunological profiles for oral delivery. These differences influence decisions around antigen stability, dosing schedules, and the selection of protective excipients or delivery vehicles.

Based on Disease Indication, attention is given to key targets such as Influenza, Norovirus, Poliovirus, and Rotavirus, where oral delivery can offer strategic benefits in terms of mucosal immunity and population-level transmission interruption. The landscape for each indication varies by historical precedent, clinical endpoints, and regulatory expectations, affecting the pace and complexity of development programs. Based on Age Group, distinctions among Adult, Geriatric, and Pediatric populations underscore the need to tailor formulations, dosing strategies, and safety monitoring to physiological and immunological differences across the lifespan.

Finally, Based on Distribution Channel, routes to market such as Hospitals & Clinics, Online Pharmacy, and Pharmacies define the operational requirements for packaging, labeling, and cold chain management, as well as the patient engagement and adherence supports needed. Integrating these segmentation lenses reveals nuanced commercial pathways: certain vaccine types may align more naturally with mass campaign models and hospital-based distribution, while others could be optimized for retail pharmacy or direct-to-consumer channels. This layered segmentation informs prioritization for developers and commercial teams as they balance scientific feasibility with route-to-market realities.

Regional insights highlighting how Americas, Europe Middle East & Africa, and Asia-Pacific variations drive differentiated regulatory, manufacturing, and distribution strategies

Regional dynamics exert a profound influence on vaccine development priorities, regulatory interactions, and distribution models, necessitating a differentiated approach across global markets. In the Americas, public-private partnerships, advanced clinical trial infrastructure, and a mature commercial ecosystem often accelerate pathway clarity for novel delivery technologies, while regional manufacturing capacity and procurement frameworks shape decisions around localization and strategic alliances. Market adoption is also influenced by payer structures and programmatic priorities that vary between national immunization programs and private sector channels.

Europe, Middle East & Africa present a spectrum of regulatory environments and healthcare delivery models that require adaptive strategies. In some European markets, harmonized regulatory processes and strong pharmacovigilance systems facilitate lifecycle planning, whereas in certain Middle Eastern and African contexts, emphasis is placed on affordability, cold chain logistics, and integration with existing immunization schedules. Collaborative initiatives and donor-supported procurement remain critical levers to expand access in regions where infrastructure limitations challenge distribution of temperature-sensitive products.

Asia-Pacific demonstrates substantial heterogeneity, with advanced manufacturing hubs, strong biopharmaceutical innovation ecosystems, and high-capacity public health programs in some markets, juxtaposed with emerging markets where infrastructure investments are ongoing. Regional supply chains, translational science collaborations, and differences in disease burden inform clinical trial design and deployment strategies. These regional insights underscore the need for tailored regulatory engagement, manufacturing footprint decisions, and distribution partnerships that align with local priorities and operational realities.

Strategic company-level insights on how incumbent manufacturers, biotech innovators, CDMOs, and allied technology firms are shaping competitive trajectories in oral vaccines

Competitive dynamics in the oral vaccine domain reflect a mix of established vaccine manufacturers, specialized biotech innovators, contract development and manufacturing organizations, and formulation technology providers. Established manufacturers bring experience in scale-up, regulatory navigation, and large-scale distribution, positioning them to accelerate late-stage candidates toward broad deployment when technical challenges are resolved. Biotechnology firms and academic spinouts contribute disruptive platform technologies and early-stage science, particularly in areas such as mucosal immunology, oral mRNA delivery, and protective excipient systems.

Contract development and manufacturing organizations play an increasingly central role by offering technical expertise in specialized formulation, encapsulation, and fill-and-finish processes that are critical for oral product viability. Collaboration between platform owners and CDMOs often determines speed to clinic and commercial scalability. Additionally, companies focused on cold chain optimization, packaging innovation, and digital supply chain solutions are creating complementary capabilities that reduce logistical friction and improve adherence monitoring.

Strategic partnerships, licensing arrangements, and public-private collaborations are recurring motifs, enabling risk-sharing and leveraging of complementary strengths. Intellectual property strategies and platform modularity influence competitive differentiation, as does the ability to generate robust safety and immunogenicity data across diverse populations. For stakeholders evaluating partnership prospects or competitive positioning, the emphasis is on technological fit, regulatory experience, manufacturing scalability, and the capacity to address end-to-end delivery challenges.

Actionable recommendations for leaders to accelerate oral vaccine development through technology investment, regulatory engagement, supply chain diversification, and targeted commercialization

Industry leaders should adopt a proactive, multi-dimensional strategy to translate scientific promise into accessible oral vaccine solutions while managing commercial and geopolitical risks. First, invest in platform capabilities that address formulation stability and mucosal immunogenicity, including partnerships with formulation specialists and academic centers to accelerate preclinical learnings and de-risk clinical translation. Simultaneously, integrate regulatory strategy early by engaging with agencies to clarify evidence requirements for novel delivery routes, thereby shortening development timelines and reducing uncertainty.

Operationally, diversify supply chains to mitigate exposure to trade policy shifts and material bottlenecks. Establish strategic relationships with regional manufacturing partners and CDMOs to enable flexible production footprints and responsive scaling. On the commercial side, develop distribution models that align with target demographics and channels-hospitals and clinics for high-acuity programs, pharmacies for routine adult immunizations, and online pharmacy solutions to enhance access and adherence in digitally enabled markets. Complement these efforts with digital tools for patient education, scheduling, and post-market surveillance.

Finally, prioritize stakeholder engagement to build confidence among payers, public health authorities, and community leaders. Invest in robust real-world evidence generation and pharmacovigilance frameworks to demonstrate safety and effectiveness across age groups. By balancing scientific rigor, regulatory foresight, operational resilience, and targeted commercial execution, industry leaders can position their portfolios to capture the full potential of oral vaccine innovations.

Transparent research methodology combining expert primary interviews, literature synthesis, case study analysis, and data triangulation to ensure balanced and actionable insights

This research synthesis is underpinned by a rigorous methodology that integrates primary and secondary inputs to ensure robust, defensible conclusions. Primary research included structured interviews and consultations with subject-matter experts from vaccine development, clinical research, regulatory affairs, manufacturing operations, and public health procurement, providing practical insights into technical challenges and strategic priorities. These engagements were complemented by analysis of relevant peer-reviewed literature, clinical trial registries, regulatory guidance, and technical white papers to ground findings in contemporary science and policy.

Data synthesis employed cross-validation techniques to reconcile differing perspectives and triangulate conclusions, placing particular emphasis on reproducibility of clinical and operational observations. The study also reviewed anonymized case examples of process development and distribution implementations to extract transferable lessons and risk mitigation strategies. Quality assurance steps included expert review cycles, methodological transparency for key assumptions, and iterative refinement based on stakeholder feedback to enhance applicability across diverse organizational contexts.

Where appropriate, the methodology identified areas of uncertainty and recommended targeted research to address gaps, such as comparative immunogenicity studies across delivery platforms and operational pilots for alternative distribution channels. The approach balances depth and pragmatism to deliver insights that are both scientifically grounded and operationally actionable for decision-makers.

Conclusive synthesis emphasizing the promise of oral vaccines, residual scientific and operational challenges, and the need for coordinated industry and policy action

In conclusion, oral vaccines represent a strategic opportunity to broaden the toolkit for disease prevention by offering needle-free administration, potential improvements in mucosal immunity, and distribution efficiencies that align with contemporary public health priorities. Scientific and technological advances are progressively addressing historical barriers related to antigen stability and gastrointestinal delivery, while regulatory pathways are becoming more navigable through proactive engagement. Yet, challenges remain, including the need for robust safety and efficacy data across age cohorts, scalable manufacturing processes, and adaptive distribution models that handle variable infrastructure capacities.

External factors such as trade policy shifts and regional heterogeneity in healthcare delivery further complicate the pathway to broad adoption, underscoring the importance of resilient supply chain design and region-specific strategies. Industry players that combine platform innovation, strategic partnerships, and operational agility will be best positioned to translate oral vaccine potential into sustainable public health impact. Ultimately, success will require coordinated effort among developers, regulators, manufacturers, payers, and public health stakeholders to ensure that promising technologies are translated into accessible, safe, and effective interventions that meet the needs of diverse populations.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing investment in probiotic-based oral vaccine formulations for enhanced mucosal immunity
  • 5.2. Regulatory approvals driving development of cold-chain-free oral vaccines in emerging markets
  • 5.3. Adoption of edible plant-based oral vaccines to reduce production costs and improve patient compliance
  • 5.4. Integration of nanotechnology carriers for targeted antigen delivery in oral vaccine platforms
  • 5.5. Expansion of oral polio vaccine eradication campaigns following strategic global partnerships and funding

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oral Vaccine Market, by Vaccine Type

  • 8.1. Conjugate Vaccines
  • 8.2. Inactivated Vaccines
  • 8.3. Live Attenuated Vaccines
  • 8.4. Mrna Vaccines
  • 8.5. Subunit Vaccines

9. Oral Vaccine Market, by Disease Indication

  • 9.1. Influenza
  • 9.2. Norovirus
  • 9.3. Poliovirus
  • 9.4. Rotavirus

10. Oral Vaccine Market, by Age Group

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Oral Vaccine Market, by Distribution Channel

  • 11.1. Hospitals & Clinics
  • 11.2. Online Pharmacy
  • 11.3. Pharmacies

12. Oral Vaccine Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Oral Vaccine Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Oral Vaccine Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. AstraZeneca plc
    • 15.3.2. Bharat Biotech International Limited
    • 15.3.3. Emergent BioSolutions Inc.
    • 15.3.4. GlaxoSmithKline plc
    • 15.3.5. Merck & Co., Inc.
    • 15.3.6. Moderna, Inc
    • 15.3.7. PT Bio Farma (Persero)
    • 15.3.8. Sanofi S.A.
    • 15.3.9. Sinovac Biotech Ltd
    • 15.3.10. Valneva SE

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORAL VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ORAL VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ORAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ORAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ORAL VACCINE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ORAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ORAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ORAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ORAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ORAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ORAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ORAL VACCINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ORAL VACCINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ORAL VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ORAL VACCINE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ORAL VACCINE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ORAL VACCINE MARKET SIZE, BY CONJUGATE VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ORAL VACCINE MARKET SIZE, BY CONJUGATE VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ORAL VACCINE MARKET SIZE, BY CONJUGATE VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ORAL VACCINE MARKET SIZE, BY CONJUGATE VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ORAL VACCINE MARKET SIZE, BY CONJUGATE VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ORAL VACCINE MARKET SIZE, BY CONJUGATE VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ORAL VACCINE MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ORAL VACCINE MARKET SIZE, BY MRNA VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ORAL VACCINE MARKET SIZE, BY MRNA VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ORAL VACCINE MARKET SIZE, BY MRNA VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ORAL VACCINE MARKET SIZE, BY MRNA VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ORAL VACCINE MARKET SIZE, BY MRNA VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORAL VACCINE MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ORAL VACCINE MARKET SIZE, BY INFLUENZA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORAL VACCINE MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ORAL VACCINE MARKET SIZE, BY INFLUENZA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORAL VACCINE MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ORAL VACCINE MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORAL VACCINE MARKET SIZE, BY NOROVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ORAL VACCINE MARKET SIZE, BY NOROVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORAL VACCINE MARKET SIZE, BY NOROVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ORAL VACCINE MARKET SIZE, BY NOROVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORAL VACCINE MARKET SIZE, BY NOROVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ORAL VACCINE MARKET SIZE, BY NOROVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORAL VACCINE MARKET SIZE, BY POLIOVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ORAL VACCINE MARKET SIZE, BY POLIOVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORAL VACCINE MARKET SIZE, BY POLIOVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ORAL VACCINE MARKET SIZE, BY POLIOVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORAL VACCINE MARKET SIZE, BY POLIOVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ORAL VACCINE MARKET SIZE, BY POLIOVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORAL VACCINE MARKET SIZE, BY ROTAVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ORAL VACCINE MARKET SIZE, BY ROTAVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORAL VACCINE MARKET SIZE, BY ROTAVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ORAL VACCINE MARKET SIZE, BY ROTAVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ORAL VACCINE MARKET SIZE, BY ROTAVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ORAL VACCINE MARKET SIZE, BY ROTAVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ORAL VACCINE MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ORAL VACCINE MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ORAL VACCINE MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ORAL VACCINE MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ORAL VACCINE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ORAL VACCINE MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ORAL VACCINE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ORAL VACCINE MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORAL VACCINE MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ORAL VACCINE MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ORAL VACCINE MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ORAL VACCINE MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ORAL VACCINE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ORAL VACCINE MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ORAL VACCINE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ORAL VACCINE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ORAL VACCINE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ORAL VACCINE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ORAL VACCINE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ORAL VACCINE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ORAL VACCINE MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ORAL VACCINE MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ORAL VACCINE MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ORAL VACCINE MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ORAL VACCINE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ORAL VACCINE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ORAL VACCINE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ORAL VACCINE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ORAL VACCINE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ORAL VACCINE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ORAL VACCINE MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ORAL VACCINE MARKET SIZE, BY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ORAL VACCINE MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ORAL VACCINE MARKET SIZE, BY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ORAL VACCINE MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ORAL VACCINE MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ORAL VACCINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ORAL VACCINE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. AMERICAS ORAL VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS ORAL VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 107. AMERICAS ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 109. AMERICAS ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 111. AMERICAS ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 118. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 120. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 124. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 130. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 134. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 145. EUROPE ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. EUROPE ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPE ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 160. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 164. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 165. AFRICA ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. AFRICA ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. AFRICA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. AFRICA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. AFRICA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 170. AFRICA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 171. AFRICA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. AFRICA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. AFRICA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 174. AFRICA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ORAL VACCINE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ORAL VACCINE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. ASEAN ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. ASEAN ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. ASEAN ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. ASEAN ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. ASEAN ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 192. ASEAN ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 193. ASEAN ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. ASEAN ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. ASEAN ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 196. ASEAN ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 197. GCC ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GCC ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GCC ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. GCC ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. GCC ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 202. GCC ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 203. GCC ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GCC ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GCC ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. GCC ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 217. BRICS ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. BRICS ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. BRICS ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. BRICS ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. BRICS ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 222. BRICS ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 223. BRICS ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. BRICS ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. BRICS ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. BRICS ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. G7 ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. G7 ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. G7 ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. G7 ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. G7 ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 232. G7 ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 233. G7 ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. G7 ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. G7 ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. G7 ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. NATO ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. NATO ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. NATO ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. NATO ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. NATO ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 242. NATO ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 243. NATO ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. NATO ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. NATO ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. NATO ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. UNITED STATES ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED STATES ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. UNITED STATES ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 252. UNITED STATES ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 253. UNITED STATES ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. UNITED STATES ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. UNITED STATES ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. UNITED STATES ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. CANADA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. CANADA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. CANADA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 260. CANADA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 261. CANADA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. CANADA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. CANADA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. CANADA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. MEXICO ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. MEXICO ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. MEXICO ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 268. MEXICO ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 269. MEXICO ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. MEXICO ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. MEXICO ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 272. MEXICO ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 273. BRAZIL ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. BRAZIL ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. BRAZIL ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 276. BRAZIL ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 277. BRAZIL ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. BRAZIL ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. BRAZIL ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. BRAZIL ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 284. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 285. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 288. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 289. GERMANY ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. GERMANY ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. GERMANY ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 292. GERMANY ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 293. GERMANY ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GERMANY ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GERMANY ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. GERMANY ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. FRANCE ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. FRANCE ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. FRANCE ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 300. FRANCE ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 301. FRANCE ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 302. FRANCE ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 303. FRANCE ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 304. FRANCE ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 305. RUSSIA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. RUSSIA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. RUSSIA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 308. RUSSIA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 309. RUSSIA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 310. RUSSIA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 311. RUSSIA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 312. RUSSIA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 313. ITALY ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. ITALY ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. ITALY ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 316. ITALY ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 317. ITALY ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 318. ITALY ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 319. ITALY ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 320. ITALY ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 321. SPAIN ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. SPAIN ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 323. SPAIN ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 324. SPAIN ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 325. SPAIN ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 326. SPAIN ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 327. SPAIN ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 328. SPAIN ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 329. CHINA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 330. CHINA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 331. CHINA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 332. CHINA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 333. CHINA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 334. CHINA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 335. CHINA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 336. CHINA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 337. INDIA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 338. INDIA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 339. INDIA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 340. INDIA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 341. INDIA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 342. INDIA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 343. INDIA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 344. INDIA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 345. JAPAN ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 346. JAPAN ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 347. JAPAN ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 348. JAPAN ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 349. JAPAN ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 350. JAPAN ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 351. JAPAN ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 352. JAPAN ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 353. AUSTRALIA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 354. AUSTRALIA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 355. AUSTRALIA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 356. AUSTRALIA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 357. AUSTRALIA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 358. AUSTRALIA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 359. AUSTRALIA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 360. AUSTRALIA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 361. SOUTH KOREA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 362. SOUTH KOREA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 363. SOUTH KOREA ORAL VACCINE MARKET SIZE, BY DISEASE IND